Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals plc executive reports tax-related share disposition. EVP and Chief Commercial Officer Samantha Pearce had 2,503 Ordinary Shares withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. After this tax-withholding transaction, she directly owns 50,272 Ordinary Shares.
Jazz Pharmaceuticals EVP Robert Iannone, Global Head of R&D and CMO, reported a tax-related share disposition. On March 5, 2026, 6,209 ordinary shares were withheld at a price of 188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units.
Following this tax-withholding disposition, Iannone directly holds 88,871 ordinary shares of Jazz Pharmaceuticals. This transaction reflects administrative share withholding rather than an open-market purchase or sale.
Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported two share dispositions. On March 9, 2026, she completed an open-market sale of 1,287 ordinary shares at a weighted average price of $182.94, leaving 6,512 shares directly owned afterward.
On March 5, 2026, she disposed of 1,436 ordinary shares at $186.7723 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, resulting in 7,799 shares directly owned following that transaction.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported a tax-related share transaction. On March 5, 2026, 7,065 ordinary shares were disposed of at $188.69 per share to satisfy tax obligations from vesting restricted stock units. After this withholding transaction, she directly owned 152,630 ordinary shares.
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported a tax-related share disposition. On March 5, 2026, 5,000 Ordinary Shares of Jazz were withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. This was recorded as a tax-withholding disposition rather than an open-market sale, and Patil’s directly held stake after the transaction was 53,818 Ordinary Shares.
Patricia Carr submitted a Form 144 notice reporting proposed sales of Common stock and recent transactions. The filing lists restricted stock items of 342, 294, 353 and 298 shares dated 03/05/2026. It also records sales during the past three months: 1,436 shares for $268,544.91 on 03/05/2026, 1,117 shares for $213,243.45 on 02/27/2026, and 1,253 shares for $243,810.00 on 02/26/2026.
JAZZ filed a Form 144 reporting proposed and recent transactions in common stock. The filing lists restricted stock vesting dated 03/05/2026 under "Issuer" for compensation. It also lists securities sold in the past three months by Patricia Carr on 12/05/2025, 02/26/2026, and 02/27/2026 with numeric entries 4660/797783.00, 1253/243810.00, and 1117/213243.00 respectively.
ETRADE Financial Corporation submitted a Form 144 notice regarding the proposed sale of restricted common stock dated 03/05/2026 tied to compensation. The filing also lists securities sold during the past three months by Mary Elizabeth Henderson on 12/09/2025 (2,338 common; $396,314.38) and 02/26/2026 (5,343 common; $1,039,626.50).
Jazz Pharmaceuticals director Bruce C. Cozadd reported selling a total of 6,000 ordinary shares of JAZZ in open-market transactions on March 3, 2026. The sales occurred in three blocks at weighted average prices of $186.0853, $186.7340 and $187.8444, executed under a Rule 10b5-1 trading plan. Following these planned sales, Cozadd directly owns 405,796 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals submitted a Form 144 indicating intended sales of common stock through Merrill Lynch with an associated date of 03/03/2026. The filing lists stock option-related lots dated 11/01/2021 (483 shares), 12/01/2021 (2,952 shares) and 01/03/2022 (2,565 shares).